FDA — authorised 27 January 2016
- Application: NDA204326
- Marketing authorisation holder: NEOS THERAPS
- Local brand name: ADZENYS XR-ODT
- Indication: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE — ORAL
- Status: approved
FDA authorised ADZENYS XR-ODT on 27 January 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 27 January 2016; FDA has authorised it.
NEOS THERAPS holds the US marketing authorisation.